-
[show abstract]
[hide abstract]
ABSTRACT: To study the effects of estradiol (E2) and medroxyprogesterone acetate (MPA) on the growth of drug resistant human epithelial ovarian cancer cell line.
OVCAR-3 cells, treated by different concentrations of E2, MPA and verapamil, were examined for their growth inhibitions with methyl thiazolyl tetrazolium (MTT, a tetrazolium dye) rapid photocolorimetric assay.
OVCAR-3 cell growth was inhibited by E2 at high concentrations (10.00-100.00 mumol/L) and by MPA at 100.00 mumol/L, while lower concentrations of E2 (0.01-1.00 mumol/L) and MPA (0.01-10.00 mumol/L) had no effect on OVCAR-3 cell growth, neither stimulation nor inhibition. The effect of E2 combined with MPA was more obvious than either one used separately. E2 and MPA in combination with doxorubin showed a synergistic inhibition effect on OVCAR-3 cell growth, which suggested that both of them could reverse the doxorubin resistance of OVCAR-3 cell line. The inhibition effect of Verapamil combined with doxorubin was obviously weaker than that of E2 and MPA.
E2 and MPA could reverse the doxorubin resistance of OVCAR-3 cell line and their inhibition were more obvious than that of verapamil, which suggested that E2 and MPA may be used clinically for adjuvant chemotherapy.
Zhonghua fu chan ke za zhi 12/1999; 34(11):670-3.
-
[show abstract]
[hide abstract]
ABSTRACT: To detect breast cancer susceptibility gene (BRCA1) mutation in ovarian cancer and to look for correlations between BRCA1 mutation and hereditary ovarian cancer.
Mutation of BRCA1 gene in 4 patients with hereditary ovarian cancer and 31 patients with sporadic ovarian cancer were screened by polymerase chain reaction-single strand conformation polymorphism analysis with non-isotopic silver staining method.
2 mutations of BRCA1 gene were found in 2 of 3 patients belonged to hereditary breast-ovarian cancer syndrom (HBOC) which were located in exon 2 and 21 respectively. No mutation was found in 31 cases of sporadic ovarian cancer and 1 case of hereditary site-specific ovarian cancer.
BRCA1 mutation was probably closely related to hereditary breast-ovarian cancer syndrome. Detection of BRCA1 gene mutation was helpful to diagnose HBOC families.
Zhonghua fu chan ke za zhi 12/1998; 33(11):676-8.
-
[show abstract]
[hide abstract]
ABSTRACT: To study the effects on biologic behavior in cells obtained from human ovarian cancer cell line SKOV-3 into which the wild-type p53 cDNA was introduced.
Recombinant eukaryotic expression vector pC53-SN3 containing full-length human wild-type p53 cDNA and vector containing neomycin resistance gene only were introduced by lipofectamine-mediated gene transfection into SKOV-3 cell line which does not express endogenous p53. The clones obtained were observed for their biologic behavior.
(1) 2 clones named pC53 and 2 clones named pNeo were obtained after pC53-SN3 and vector transfection respectively; (2) The morphology of cells either from pC53 or from pNeo did not change significantly with respect to their parental SKOV-3; (3) The growth rate of cells from pC53 was much slower than that from SKOV-3, while the cell growth curve of pNeo was similar to that of SKOV-3; (4) The number of colones formed in the soft-agar by pC53 was significantly less than that by SKOV-3 or by pNeo; (5) The percentage of phase G1/G0 of pC53 was much higher than that of SKOV-3 and pNeo.
Wild-type p53 cDNA may be considered as one of the target genes for the gene therapy of ovarian cancer.
Zhonghua fu chan ke za zhi 01/1998; 32(12):715-7.
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the relationship between (LH-CG) receptor expression and prognosis in epithelial ovarian cancer.
The relative quantity of LH-CG receptor protein of epithelial ovarian cancer tissuse was detected with semiquantitative western immunobloting in 40 cases. The LH-CG receptor protein was located with immunohistochemistry. The LH-CG receptor was termed high expression if its concentration was more than and/or equal to the median, and low expression if its concentration was less than the median. 36 of the 40 cases were followed up at various intervals, the longest follow up period was 56 months. There were 16 cases with high LH-CG expression and 20 cases with low LH-CG receptor expression in which 9 cases died.
The positive rate of LH-CG receptor protein expression was 72.5% (29/40). The level of LH-CG receptor protein expression in patients with stages I and II was higher than that in patients with stages III and IV, but it is not significant (P > 0.05). The LH-CG receptor concentration in the well-differentiated cancer group was twice as much as that in the poorly-differentiated cancer group. The difference between the well-differentiated group and the poorly-differentiated group was significant (P < 0.05). The 1-year and 3-year survival rates were 83.94% and 67.15% respectively in the high LH-CG receptor expression group. Both of the 1-year and 3-year survival rates were 33. 34% in the low LH-CG receptor expression group. The survival rates of the high expression group was significantly higher than those of the low expression group (P < 0.05). LH-CG receptor expression did not correlate with age, lymph node metastases, the size of residual tumor and CA125.
The prognosis of patients with high LH-CG receptor expression is better than that of those with low expression.
Zhonghua fu chan ke za zhi 12/1997; 32(12):742-5.
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the clinical and pathological characteristics of epithelial ovarian carcinoma in patients with age under 40.
From Jan 1978 to Dec 1992, 54 cases with epithelial ovarian carcinoma under 40 years old were admitted to our hospital and enrolled in the study group, another 54 patients suffered from the same disease with age over 40 in the same period were served as control. Comparison analysis for clinical and pathologic data of 2 groups was performed using SPSS and SURVALC statistics software.
Main complaint because of either pelvic mass or abdominal mass found by chance was more common in study group (46.3%) than that in control group (27.8%). whereas because of symptoms was less common in study group (53.7%) than in control group (72.2%). Other parameters such as early stage (I and II) rate (61.1%), unilateral tumor rate (68.5%), average maximum diameter of tumor (13.6 cm), highly differentiated rate (50%) and the possibility for tumor reductive surgery were higher in study group than in control group. The difference of histological pattern and chemotherapy between 2 groups was not significant. Single variate analysis showed that the prognosis was better in study group. The 2-year and 5-year survival rates were 69.8% and 50.2% respectively. No recurrence was found in the 8 patients in whom the contralateral healthy ovary remained. However multiple variate analysis indicated that age was not a prognostic factor.
Epithelial ovarian carcinoma was prone to be lower degree malignancy in patients under 40 years therefore the prognosis of them was better. It might be resonable to have healthy ovary left in some select cases.
Zhonghua fu chan ke za zhi 10/1997; 32(9):548-51.
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the prognosis change and prognostic factors of advanced epithelial ovarian cancer in recent over twenty years.
One hundred and fourty patients with advanced epithelial ovarian cancer were analyzed. They were divided into two groups based on their operation time. 56 patients operated before Jan. 1980 were included in the first group, and the other 84 patients in the second group. Kaplan-Meier survival curves of the two groups were calculated, and Cox model was used to evaluate the prognostic factors of the disease at univariate and multivariate levels using SPSS and SURVCALC software.
There was no pathological difference in between the two groups, but the patients in the second group received more aggressive chemotherapy. The overall 1-, 2-, and 5-year survival rates were 61.2%, 32.1%, and 8.5%, respectively. In the first group they were 42.3%, 29.6% and 4.5% respectively and in the second group 69.3%, 36.2%, and 11.2% respectively. The prognosis of the patients in the second group was better than that in the first group, P < 0.05. Univariate analysis revealed that stage, grade, residual tumor size and chemotherapy were significant predictors of patients' outcome. COX regression analysis identified that they were all independent prognostic factors. The patients with advanced, low grade, residual tumor (> 2 cm) had poor prognosis. The prognosis of the patients who received equal or more than four, especially six cycles combined chemotherapy was improved.
The prognosis of the patients with advanced ovarian cancer has improved in recent over 10 years, higher optimal cytoreductive rate and equal or more than six cycles combined chemotherapy are important measures for the better prognosis of advanced ovarian cancer.
Zhonghua fu chan ke za zhi 04/1997; 32(3):159-62.
-
[show abstract]
[hide abstract]
ABSTRACT: To detect p53 mutations in human ovarian cancer and to look for correlations between p53 mutation and clinicopathologic features.
Mutations in exons 5-8 of p53 gene in 41 patients with primary ovarian cancer were screened by polymerase chain reaction-single strand conformation polymorphism analysis with non-isotopic silver staining method.
Mutations of p53 were found in 17 cases (41.5%); p53 mutation was not correlated with the age, the FIGO stage and the histologic type of the patients. However, it was associated with grade and lymph node metastasis in a univariate analysis.
Mutations of p53 occur commonly in human ovarian cancer. p53 mutation is an early event in ovarian carcinogenesis and may serve as a genetic marker for early diagnosis and prognosis.
Zhonghua fu chan ke za zhi 12/1996; 31(11):660-3.
